Keryx Biopharmaceuticals, Inc. (KERX) Reaches $4.67 After 3.00% Up Move; Essent Group Ltd. (ESNT) Had 8 Bulls

December 8, 2017 - By Marie Mckinney

The stock of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a huge mover today! The stock increased 3.09% or $0.14 during the last trading session, reaching $4.67. About 704,075 shares traded. Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has risen 13.56% since December 8, 2016 and is uptrending. It has underperformed by 3.14% the S&P500.The move comes after 7 months positive chart setup for the $556.77M company. It was reported on Dec, 8 by Barchart.com. We have $4.81 PT which if reached, will make NASDAQ:KERX worth $16.70M more.

Among 10 analysts covering Essent Group (NYSE:ESNT), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Essent Group had 35 analyst reports since August 12, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Friday, November 3 by Deutsche Bank. The stock of Essent Group Ltd. (NYSE:ESNT) has “Overweight” rating given on Friday, November 10 by Barclays Capital. The rating was downgraded by JP Morgan to “Neutral” on Friday, April 21. The stock of Essent Group Ltd. (NYSE:ESNT) has “Buy” rating given on Tuesday, May 9 by Bank of America. The rating was upgraded by BTIG Research to “Buy” on Tuesday, September 12. The stock of Essent Group Ltd. (NYSE:ESNT) earned “Hold” rating by Keefe Bruyette & Woods on Monday, May 29. Deutsche Bank maintained the shares of ESNT in report on Tuesday, August 8 with “Buy” rating. The stock has “Hold” rating by Keefe Bruyette & Woods on Monday, August 7. Keefe Bruyette & Woods downgraded the shares of ESNT in report on Friday, August 5 to “Market Perform” rating. Barclays Capital maintained Essent Group Ltd. (NYSE:ESNT) on Wednesday, September 7 with “Overweight” rating. See Essent Group Ltd. (NYSE:ESNT) latest ratings:

28/11/2017 Broker: Wells Fargo Rating: Buy New Target: $52.0
09/11/2017 Broker: BTIG Research Rating: Buy New Target: $49.0 Maintain
09/11/2017 Broker: Keefe Bruyette & Woods Rating: Buy New Target: $51.0 Maintain
10/11/2017 Broker: Barclays Capital Rating: Overweight Old Target: $45 New Target: $46 Maintain
03/11/2017 Broker: Deutsche Bank Old Rating: Buy New Rating: Hold Old Target: $49 Downgrade
25/10/2017 Broker: Deutsche Bank Rating: Buy Old Target: $48 New Target: $49 Maintain
11/10/2017 Broker: Compass Point Rating: Buy New Target: $50.0
12/09/2017 Broker: BTIG Research Old Rating: Neutral New Rating: Buy New Target: $44 Upgrade
23/08/2017 Broker: Keefe Bruyette & Woods Rating: Buy Upgrade
23/08/2017 Broker: Wood Old Rating: Market Perform New Rating: Outperform Upgrade

Among 15 analysts covering Keryx Biopharmaceuticals (NASDAQ:KERX), 6 have Buy rating, 2 Sell and 7 Hold. Therefore 40% are positive. Keryx Biopharmaceuticals had 36 analyst reports since July 23, 2015 according to SRatingsIntel. The rating was maintained by Maxim Group with “Buy” on Thursday, February 25. The firm has “Sell” rating by Citigroup given on Thursday, September 3. Maxim Group maintained Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) rating on Thursday, July 20. Maxim Group has “Buy” rating and $900 target. BTIG Research maintained the shares of KERX in report on Thursday, August 6 with “Sell” rating. Stifel Nicolaus maintained it with “Buy” rating and $9 target in Friday, February 26 report. The stock of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) earned “Outperform” rating by Raymond James on Tuesday, August 2. The firm has “Hold” rating by Stifel Nicolaus given on Wednesday, November 8. The stock of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has “Neutral” rating given on Friday, February 26 by JP Morgan. The stock of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has “Market Perform” rating given on Thursday, July 23 by Cowen & Co. The stock of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) earned “Hold” rating by Cowen & Co on Friday, June 16.

Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with renal disease in the United States. The company has market cap of $556.77 million. It markets its lead product Auryxia , an orally available, absorbable, iron medicine for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. It currently has negative earnings. The firm has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan.

Investors sentiment increased to 1.97 in 2017 Q2. Its up 0.66, from 1.31 in 2017Q1. It is positive, as 11 investors sold Keryx Biopharmaceuticals, Inc. shares while 18 reduced holdings. 18 funds opened positions while 39 raised stakes. 76.46 million shares or 15.57% more from 66.16 million shares in 2017Q1 were reported. Susquehanna Int Llp owns 235,708 shares. Swiss Bancorp holds 0% in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) or 130,500 shares. D E Shaw Communication reported 0% of its portfolio in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Citigroup reported 36,207 shares. 168,979 were accumulated by Ny State Common Retirement Fund. Westpac Bk holds 0% of its portfolio in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) for 54,010 shares. State Street Corp invested 0% in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Fincl Architects has 0% invested in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) for 282 shares. Boston reported 409,051 shares or 0% of all its holdings. Citadel Advisors Ltd Llc owns 108,115 shares. Pekin Singer Strauss Asset Mngmt Il reported 0.03% of its portfolio in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Moreover, Jpmorgan Chase has 0% invested in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). California State Teachers Retirement stated it has 0% in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). 64,782 were accumulated by State Board Of Administration Of Florida Retirement System. 852,162 are owned by Geode Cap Management Lc.

Analysts await Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) to report earnings on March, 7. They expect $-0.18 earnings per share, up 43.75% or $0.14 from last year’s $-0.32 per share. After $-0.20 actual earnings per share reported by Keryx Biopharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -10.00% EPS growth.

Investors sentiment increased to 1.36 in 2017 Q2. Its up 0.10, from 1.26 in 2017Q1. It is positive, as 18 investors sold Essent Group Ltd. shares while 65 reduced holdings. 32 funds opened positions while 81 raised stakes. 79.27 million shares or 1.31% more from 78.24 million shares in 2017Q1 were reported. Susquehanna Group Incorporated Llp holds 0% of its portfolio in Essent Group Ltd. (NYSE:ESNT) for 124,288 shares. Stanley invested in 0.17% or 16,973 shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 3,145 shares. Hightower Limited Liability Co stated it has 7,980 shares. Parkside Bancorporation & Tru holds 0.02% of its portfolio in Essent Group Ltd. (NYSE:ESNT) for 1,140 shares. Bowling Port Mgmt Lc invested in 37,492 shares. Ameriprise Incorporated has invested 0% in Essent Group Ltd. (NYSE:ESNT). Captrust Advsr accumulated 500 shares or 0% of the stock. Ubs Asset Mgmt Americas holds 332,447 shares. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Invest Mngmt holds 0.04% in Essent Group Ltd. (NYSE:ESNT) or 116,300 shares. Geode Capital Management Ltd Llc owns 826,141 shares. Groesbeck Mgmt Corporation Nj has 7,900 shares for 0.22% of their portfolio. Da Davidson has 0% invested in Essent Group Ltd. (NYSE:ESNT) for 2,230 shares. Hillsdale Management holds 0.21% or 29,600 shares. Glenmede Co Na invested in 33,420 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.